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A B S T R A C T
Methylmercury is an environmental pollutant that exhibits neurotoxicity when ingested, primarily in the form of
neuropathological lesions that localize along deep sulci and ﬁssures, in addition to edematous and inﬂammatory
changes in patient cerebrums. These conditions been known to give rise to a variety of ailments that have come
to be collectively termed Minamata disease. Since prostaglandins I2 and E2 (PGI2 and PGE2) increase vascular
permeability and contribute to the progression of inﬂammatory changes, we hypothesize that methylmercury
induces the synthesis of these prostaglandins in brain microvascular endothelial cells and pericytes. To test this
theory, human brain microvascular endothelial cells and pericytes were cultured and treated with methylmer-
cury, after which the PGI2 and PGE2 released from endothelial cells and/or pericytes were quantiﬁed by enzyme-
linked immunosorbent assay while protein and mRNA expressions in endothelial cells were analyzed by western
blot analysis and real-time reverse transcription polymerase chain reaction, respectively. Experimental results
indicate that methylmercury inhibits the activity of protein tyrosine phosphatase 1B, which in turn activates the
epidermal growth factor receptor–p38 mitogen-activated protein kinase pathway that induces cyclooxygenase-2
expression. It was also found that the cyclic adenosine 3′,5′-monophosphate pathway, which can be activated by
PGI2 and PGE2, is involved in methylmercury-induced cyclooxygenase-2 expression. Since it appears that protein
tyrosine phosphatase 1 B serves as a sensor protein for methylmercury in these mechanisms, it is our belief that
the results of the present study may provide additional insights into the molecular mechanisms responsible for
edematous and inﬂammatory changes in the cerebrum of patients with Minamata disease.
1. Introduction
Methylmercury is an organometallic compound that is well-known
for its neurotoxic properties (Sanfeliu et al., 2003). However, while
such organometallic compounds are often toxic, their toxicity char-
acteristics cannot be assumed from those of either the inorganic metal
or the organic structure of the organometallic compounds (Kohri et al.,
2015). In fact, the toxicity of methylmercury is completely diﬀerent
from its inorganic mercury and methane components. In human beings,
methylmercury toxicity is characterized by neuropathological lesions
localized along deep sulci and ﬁssures in the cerebral cortex, such as
carcalin ﬁssures, and the granular cell layer in patient cerebellums (Eto,
1997). The resulting neuropathological aﬀects, which has come to be
known as Minamata disease, include concentric visual ﬁeld contraction,
articulation disorder, hearing impairment, and ataxia (Chang et al.,
1973; Uchino et al., 2005). However, while the molecular mechanisms
underlying the abovementioned localization have not yet been clariﬁed,
Eto et al. (2001) hypothesized that methylmercury induces edematous
changes that cause a circulation disorder; after which nerve cells,
especially along deep sulci and ﬁssures, are secondarily damaged in the
cerebrum. This “edema hypothesis” appears to rationally explain why
methylmercury cerebral damage tends to localize along deep sulci and
ﬁssures in the cerebral cortex. Additionally, it is likely that in-
ﬂammatory changes in the neurovascular unit (NVU) contribute to the
progression of the edematous changes (Stokum et al., 2016).
Vascular endothelial cells and pericytes are constituent cell types of
the NVU, which regulates the functions of brain microvessels such as
the blood-brain barrier (BBB) function, glucose and amino acid
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transport, and vascular tonus (Abbott et al., 2006; Bechmann et al.,
2007; Orlidge and D’Amore, 1987; Kutcher and Herman, 2009). Our
previous studies of methylmercury-induced functional cell damage
have shown that the compound also inhibits the repair of wounded
monolayers in endothelial cells by suppressing the expression of ﬁ-
broblast growth factor-2 (Hirooka et al., 2009). Additionally, it has
been shown that methylmercury activates the vascular endothelial
growth factor (VEGF) paracrine system among endothelial cells and
pericytes by inducing the expression of VEGF and VEGF receptor-2 in
pericytes and endothelial cells, respectively (Hirooka et al., 2013).
These results suggest that the activation of VEGF system suppresses the
expression of tight junction proteins (Wang et al., 2001; Fischer et al.,
2002), increases hydraulic permeability of vessels (Bates and Curry,
1996), and promotes edema formation (van Bruggen et al., 1999). Re-
cently, we reported that methylmercury induces the expression of
hyaluronan in endothelial cells and pericytes (Hirooka et al., 2017),
which can contribute to the progression of edematous change by re-
taining water in the extracellular matrix. Such methylmercury-induced
edematous changes may − at least in part − result from functional
abnormalities in brain microvascular endothelial cells and pericytes.
Prostaglandins (PGs) are arachidonic acid metabolites that are in-
volved in the inﬂammatory and subsequent edematous changes in brain
microvascular endothelial cells and pericytes. Cyclooxygenases (COXs)
metabolize arachidonic acid to prostaglandin H2 (Miyamoto et al.,
1976; Van der Ouderaa et al., 1977), which is subsequently processed
by downstream enzymes to the various prostanoids such as pros-
taglandins I2 and E2 (PGI2 and PGE2) that cause edematous and in-
ﬂammatory changes by increasing vascular permeability and vasodi-
lation (Williams, 1979). There are two COX isoforms: COX-1 and COX-
2. The expression of COX-1 is constitutive, whereas COX-2 is inducible
and involved in the inﬂammatory response (Seibert et al., 1994; Dubois
et al., 1998). The induction of COX-2 results in a shift in arachidonic
acid metabolism from the production of several prostanoids to the
preferential synthesis of PGI2 and PGE2 (Brock et al., 1999). The mi-
togen-activated protein kinase (MAPK) and cyclic adenosine 3′,5′-
monophosphate (cAMP) pathways are involved in the induction of
COX-2 expression (Tsatsanis et al., 2006).
We hypothesize that methylmercury inﬂuences PG synthesis in
brain microvascular endothelial cells and pericytes. We examined this
hypothesis using a cell culture system of these cell types with the goal of
revealing the intracellular signaling by which methylmercury induces
COX-2 to promote PGI2 synthesis in endothelial cells.
2. Materials and methods
2.1. Materials
Human brain microvascular endothelial cells and pericytes were
purchased from DS Pharma Biomedical (Osaka, Japan). Collagen-
coated tissue culture dishes and plates were obtained from AGC
Technoglass (Chiba, Japan). HuMedia-EG2 and HuMedia-SG2 were
purchased from Kurabo (Osaka, Japan). Dulbecco’s modiﬁed Eagle’s
medium (DMEM) and Ca2+, Mg2+-free phosphate-buﬀered saline
(CMF-PBS) were obtained from Nissui Pharmaceutical (Tokyo, Japan).
Methylmercury chloride was purchased from Tokyo Kasei Kogyo
(Tokyo, Japan), while bovine serum albumin (BSA), Tris base, and anti-
β-actin antibodies (20–33) were obtained from Sigma-Aldrich Chemical
(St. Louis, MO, USA).
Additionally, a mitogen-activated protein kinase (MEK1/2) in-
hibitor PD98059, a p38 MAPK inhibitor SB203580, a c-Jun N-terminal
kinase (JNK) inhibitor SP600125, a 6-keto PGF1α enzyme-linked im-
munosorbent assay (EIA) kit, and a PGE2 EIA kit were all purchased
from Cayman Chemical (Ann Arbor, MI, USA). The adenylate cyclase
inhibitor SQ22536 and human active protein tyrosine phosphatase
(PTP1B) EIA kit used in this study were obtained from R&D Systems
(Minneapolis，MN，USA). We purchased epidermal growth factor
(EGFR) inhibitor PD153035 from Calbiochem (Boston, MA, USA), a
BCA protein assay reagent kit from Pierce (Rockford，IL，USA),
Immobilon-P transfer membrane (pore size 0.45 μm) from Millipore
(Billerica，MA，USA), anti-COX-2 antibody (sc-19999) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-phosphorylated EGFR antibody (3777S), anti-phosphorylated
ERK1/2 antibody (9101S), anti-phosphorylated p38 MAPK antibody
(9211S), anti-phosphorylated JNK antibody (9255S), and horseradish
peroxidase-labeled anti-mouse and anti-rabbit antibodies were pur-
chased from Cell Signaling (Beverly, MA, USA). Fetal bovine serum
(FBS), MagicMarkTM XP western protein standard, and RNase DNase
free water were obtained from Invitrogen (Carlsbad, CA, USA). QIAzol
lysis reagent was purchased from Qiagen (Hilden, Germany), while a
High-Capacity cDNA archive kit, TaqMan Universal PCR Master Mix II,
TaqMan Gene Expression Assay (20 × ), and the primer and probe sets
used for real-time reverse transcription polymerase chain reaction (RT-
PCR) were purchased from Applied Biosystems (Foster, CA, USA). Other
reagents were purchased from Wako Purechemical (Osaka, Japan) and
Nacalai Tesque (Kyoto, Japan). Methylmercury at 10 mM was stored at
−80 °C in CMF-PBS containing L- cysteine at 10 mM until use.
2.2. Cell culture
Human brain microvascular endothelial cells and pericytes were
cultured in HuMedia-EG2 and HuMedia-SG2 medium, respectively, in
100 mm collagen-coated dishes at 37 °C in a humid atmosphere of 5%
CO2 until conﬂuent. The cells were then transferred into other 100 mm
collagen-coated dishes, 60 mm collagen-coated dishes, or 6-well col-
lagen-coated plates and cultured until conﬂuent. Next, the cells were
treated with methylmercury in fresh HuMedia EG-2 medium (en-
dothelial cells) and DMEM supplemented with 1% BSA (pericytes). In a
separate experiment, conﬂuent cell cultures were treated with
SB203580 (10, 20, 50 or 100 μM), PD153035 (2, 5, 10 or 20 μM), or
SQ22536 (10, 20 50 or 100 μM) for 3 h, and then treated with me-
thylmercury (5 μM) for 6 or 24 h. The expression levels of COX-2,
ERK1/2, JNK, p38 MAPK, and EGFR were determined by western blot
analysis as described below. We postulated that the PTP1B is a sensor
protein for methylmercury to activate the EGFR-MAPK pathway that
induces COX-2 expression. It was considered that it takes a time to
stimulate the PG production by activation of the EGFR-p38 MAPK-COX-
2 pathway. Therefore, we designed experiments to determine PTP1B
activity and EGFR phosphorylation after 20 min, MAPK phosphoryla-
tion after 1 h, and COX-2 activation/PG accumulation after 24 h of the
methylmercury treatment. Additionally, we do not show the data about
the cell viability, since we have already reported that endothelial cells
and pericytes in our system are resistant to the cytotoxicity of me-
thylmercury (Hirooka et al., 2007, 2010a,b).
2.3. Determination of PGI2 and PGE2
Human brain microvascular endothelial cells and pericytes in 6-well
culture plates were treated with methylmercury (1–3, and 5 μM) for
24 h. After treatment, the conditioned medium was harvested and used
for the determination of PGI2 measured as 6-keto PGF1α and PGE2 by
the EIA kits. The cell layer was washed twice with CMF-PBS and then
scraped oﬀ with a rubber policeman in the presence of 1.5 mL CMF-
PBS. The well was then washed with 1.5 mL CMF-PBS and the wash was
combined with the corresponding harvested cell suspension. This
combined cell suspension was then sonicated and the cell homogenate
was used for the determination of DNA content by the ﬂuorometric
assay. The 6-keto PGF1α and PGE2 accumulated in the conditioned
medium were expressed as pg/μg DNA.
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2.4. Determination of COX-2, p38 MAPK, ERK1/2, JNK, and EGFR
proteins
The human brain microvascular endothelial cells and pericytes
treated with methylmercury (1–3, and 5 μM) for 24 h in 6-well culture
plates were washed twice with ice-cold CMF-PBS and 2 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid-containing
CMF-PBS. After washing, the cells were lysed with 80 μL of 50 mM Tris-
HCl buﬀer solution (pH 6.8) containing 10% glycerol and 2% sodium
dodecyl sulfate. The ten μg proteins of the lysate were separated by
SDS-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel,
and then transferred onto an Immobilon-P membrane. Next, 5% poly-
acrylamide gel was used for EGFR separation. Membranes were treated
with 5% skim milk in 20 mM Tris-HCl buﬀer solution (pH 7.5) con-
taining 150 mM NaCl and 0.1% Tween 20, and then incubated over-
night at 4 °C with anti-COX-2 antibody (1:200)，anti-phosphorylated
EGFR antibody (1:1000), anti-phosphorylated ERK antibody (1:1000),
anti-phosphorylated p38 MAPK antibody (1:1000), anti-phosphorylated
JNK antibody (1:1000), anti-EGFR antibody (1:1000), or anti-β-actin
antibody (1:200). The membranes were then washed and incubated
with horseradish peroxidase-conjugated secondary antibodies for 1 h at
room temperature. Immunoreactive bands were visualized using en-
hanced chemiluminescence western blot detection reagents (Chemi-
Lumi One L; Nacalai, Kyoto, Japan) and scanned using a LAS 3000
Imager (Fujiﬁlm, Tokyo, Japan).
2.5. Real-time RT-PCR
Total RNA was extracted from human brain microvascular en-
dothelial cells and pericytes treated with methylmercury (1–3, and
5 μM) for 12 h in 60 mm dishes. The complementary DNA (cDNA) was
synthesized using the High-Capacity cDNA Reverse Transcription kit.
Real-time PCR was performed using Gene Ace SYBR qPCR Mixα with
10 ng cDNA and 100 nM primers on a StepOnePlus RT-PCR system
(Applied Biosystems). The thermal cycling parameters were 95 °C for
10 min, 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. COX-2 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels
were quantiﬁed using the relative standard curve method. The primer
and probe sets for COX-2 (Hs00153133-m1) and GAPDH (Hs99999905-
m1) were obtained using the TaqMan Gene Expression Assay.
2.6. PTP1B activity
Conﬂuent cultures of human brain microvascular endothelial cells in
60 mm dishes were treated with methylmercury (3 or 5 μM) for 20 min,
after which the medium was discarded and the cell layer was harvested
by scraping with a rubber policeman in the presence of 200 μL 50 mM
Tris-HCl buﬀer solution (pH7.5) containing 150 mM NaCl, 0.1% sodium
deoxycholate, 1% 3-[(3-cholamidopropyl)dimethylammonio]propane-
sulfonate, 1 mM O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-
tetraacetic acid, and 0.4 mM ethylenediaminetetraacetic acid (cell lysis
buﬀer). The cell suspension was then lysed on ice for 30 min, after which
the cell lysate was centrifuged at 2,000 × g for 5 min at 4 °C. The re-
sulting supernatant was used for the determination of active PTP1B
protein and total protein content by the human active PTP1B Duoset IC
kit and BCA protein assay reagent kit, respectively. The PTP1B activity
was deﬁned as the ratio of active PTP1B protein content to the corre-
sponding total protein content.
2.7. Statistical analysis
Results were analyzed for statistical signiﬁcance by analysis of
variance (ANOVA) and Bonferroni’s multiple t-test, when possible. P
values less than 0.05 were considered statistically signiﬁcant.
3. Results
Fig. 1 shows the eﬀects of methylmercury on the accumulation of
PGI2 and PGE2 in the conditioned medium of human brain micro-
vascular endothelial cells and pericytes. In endothelial cells, methyl-
mercury levels at 5 μM and less were found to have signiﬁcantly in-
creased the accumulation of PGI2 detected as 6-keto PGF1α in a
concentration-dependent manner after a 24-h incubation period
(Fig. 1a); however, PGE2 was not detected. It was reported that vascular
endothelial cells have an ability to synthesize PGE2 but the major
product of prostaglandins in the cells is PGI2 (Chesterman et al., 1983).
PGI2 accumulation in the conditioned pericyte medium was found to
have increased after treatment with methylmercury at 5 μM for 24 h
(Fig. 1b). Additionally, methylmercury at 5 μM signiﬁcantly increased
the PGE2 accumulation after a 24-h incubation period (Fig. 1c).
Fig. 2 shows the expression of COX-2 in human brain microvascular
endothelial cells and pericytes before and after treatment with me-
thylmercury. As can be seen in the ﬁgure, methylmercury at 5 μM and
less increased the expression of COX-2 protein in endothelial cells in a
concentration-dependent manner (Fig. 2a, left panel) and at 5 μM in
pericytes (Fig. 2a, right panel) after a 24-h incubation period. The ex-
pression level of COX-2 mRNA in endothelial cells was signiﬁcantly
elevated by methylmercury treatment at concentrations of 5 μM or less
in a concentration-dependent manner (Fig. 2b, left panel), and at 5 μM
in pericytes (Fig. 2b, right panel) after a 24-h incubation period.
Because a concentration-dependent response to methylmercury was
observed in endothelial cells but not in pericytes, the following ex-
periments were performed using endothelial cells. Since the expression
of COX-2 is upregulated by activation of MAPKs (Lin et al., 2009), both
the phosphorylation of MAPKs (p38 MAPK, ERK1/2, and JNK) and the
involvement of MAPKs in methylmercury-induced COX-2 expression
were determined (Fig. 3). The phosphorylation of ERK1/2 and JNK was
unaﬀected, whereas that of p38 MAPK was increased by methylmercury
in a concentration-dependent manner (Fig. 3a). Methylmercury-in-
duced expression of COX-2 protein was suppressed by SB203580, a p38
Fig. 1. The release of PGI2 and PGE2 from
human brain microvascular endothelial cells
and pericytes after exposure to methylmer-
cury. The cells were treated with methyl-
mercury (1–3, and 5 μM) for 24 h. The re-
leased PGI2 was detected as 6-keto PGF1. a)
The eﬀect of methylmercury on the release
of PGI2 from endothelial cells. b) The eﬀect
of methylmercury on the release of PGI2
from pericytes. c) The eﬀect of methylmer-
cury on the release of PGE2 from pericytes.
PGE2 release from endothelial cells was not
detected. Values are means ± S.E. of four
samples. **Signiﬁcantly diﬀerent from the
corresponding control, p < 0.01.
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MAPK inhibitor, thereby suggesting that the activation of the p38
MAPK signal is involved in methylmercury-induced COX-2 expression
in human brain microvascular endothelial cells (Fig. 3b).
Although the mechanism by which methylmercury activates p38
MAPK has previously been unclear, we paid speciﬁc attention to EGFR
due to the following reasons:
(1) Auto-phosphorylation occurs in EGFR, and this activation is nega-
tively regulated by the de-phosphorylating enzyme, PTP1B (Barford
et al., 1995).
(2) Electrophiles including zinc ion can inhibit the activity of PTP1B and
then activate EGFR (Bellomo et al., 2014; Iwamoto et al., 2007).
(3) Methylmercury has an electrophile characteristic.
It was found that EGFR phosphorylation was increased by treatment
with methylmercury for 20 min at levels of 1 μM and more (Fig. 4a),
and that PD153035, an EGFR inhibitor, diminished methylmercury-
induced p38 MAPK activation in a concentration-dependent manner
(Fig. 4b). This suggests that the methylmercury-induced p38 MAPK
activation is mediated by the EGFR phosphorylation. Furthermore,
methylmercury at 1 μM and more signiﬁcantly decreased the activity of
PTP1B (Fig. 4c), thus supporting the hypothesis that methylmercury
inhibits this phosphatase, although other mechanisms cannot be ex-
cluded. Taken together, these results suggest that methylmercury-in-
duced COX-2 expression is mediated by the EGFR-p38 MAPK pathway,
which is activated by PTP1B inhibition.
Both PGI2 and PGE2 can increase the intracellular level of cAMP by
Fig. 2. The expression of COX-2 in from human brain microvascular
endothelial cells and pericytes after exposure to methylmercury. a)
The eﬀect of methylmercury on the expression of COX-2 protein. The
cells were treated with methylmercury (1–3, and 5 μM) for 24 h b)
The eﬀect of methylmercury on the expression of COX-2 mRNA. The
cells were treated with methylmercury (1–3, and 5 μM) for 12 h.
Values are means ± S.E. of four samples. **Signiﬁcantly diﬀerent
from the corresponding control, p < 0.01.
Fig. 3. Involvement of the phosphorylation
of MAPKs (p38 MAPK, ERK1/2, and JNK) in
the induction of COX-2 protein by methyl-
mercury in human brain microvascular en-
dothelial cells. a) The eﬀect of methylmer-
cury on the phosphorylation of MAPKs. The
cells were treated with methylmercury (1–3,
and 5 μM) for 1 h. Western blot analysis (left
panel) and its quantitative analysis (right
panel). b) The eﬀect of p38 MAPK inhibitor
SB203580 on the expression of COX-2 pro-
tein. The cells were treated with methyl-
mercury (1–3, and 5 μM) for 24 h after
pretreatment with SB203580 (10, 20, 50,
and 100 μM) for 3 h. Western blot analysis
(left panel) and its quantitative analysis
(right panel).
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activation of adenylate cyclase through the activation of relaxant
prostaglandin receptors− EP2, EP4, or IP (Narumiya and Furuyashiki,
2011). Additionally, COX-2 expression can be upregulated by the
cAMP-protein kinase A signaling pathway (Debey et al., 2003; Steinert
et al., 2009; Díaz-Muñoz et al., 2012). Based on these results, in-
volvement of the cAMP pathway in methylmercury-induced COX-2
expression was determined (Fig. 4d). More speciﬁcally, after a 24-h
incubation period, it was shown that SQ22536, an adenylate cyclase
inhibitor, diminished the induction of COX-2 expression by methyl-
mercury in a concentration-dependent manner. This suggests that there
is a positive feedback loop among methylmercury, COX-2, and cAMP
that induces COX-2 expression in endothelial cells.
4. Discussion
It is important to clarify the eﬀects of methylmercury on the
synthesis of PGI2 and PGE2 in brain vascular cells in order to under-
stand the inﬂammatory changes that accompany the progression of
edematous variations in the brain after methylmercury exposure. The
following results were obtained from our experiments using a cell
culture system:
(1) Methylmercury increased the release of PGI2 from human brain
microvascular endothelial cells and both PGI2 and PGE2 from
human brain microvascular pericytes.
(2) Methylmercury induced the expression of COX-2 in both en-
dothelial cells and pericytes.
(3) Inhibition of methylmercury-activated p38 MAPK suppressed me-
thylmrcury-induced COX-2 expression.
(4) Methylmercury activated EGFR and inhibited PTP1B activity. In
addition, the inhibition of EGFR suppressed the activation of p38
MAPK by methylmercury.
(5) Inhibition of adenylate cyclase suppressed the expression of COX-2
induced by methylmercury.
When these results are examined together, it can be postulated that
methylmercury activates EGFR by inhibition of PTP1B, and that this
activation consequently induces the activation of p38 MAPK that in-
creases the expression of COX-2. The induced COX-2 then increases the
synthesis of PGI2 in endothelial cells and both PGI2 and PGE2 in brain
microvessel pericytes. Additionally, it is suggested that PGI2- and PGE2-
induces the activation of adenylate cyclase (Coleman et al., 1994;
Narumiya et al., 1999) and increases the intracellular cAMP that in-
duces the COX-2 expression (Debey et al., 2003; Steinert et al., 2009;
Díaz-Muñoz et al., 2012). In other words, the EGFR–p38 MAPK
pathway mediates the methylmercury-induced expression of COX-2
that synthesizes PGI2 and PGE2 in vascular endothelial cells and peri-
cytes. In addition to this intracellular signaling cascade, the PGI2/
PGE2–adenylate cyclase–cAMP–protein kinase A pathway may serve as
a positive feedback loop that enhances COX-2 induction by methyl-
mercury, since protein kinase A is a cAMP-dependent protein kinase
(Shabb, 2001) and induce COX-2 expression (Debey et al., 2003).
Furthermore, PTP1B appears to be a sensor protein for methylmercury,
which initiates the consequent intracellular signaling. These biological
chain reactions are summarized in Fig. 5.
Although PGI2 and PGE2 have multiple physiological roles, one of
their common functions is involvement with the inﬂammatory changes
caused by an increase in vascular relaxation and permeability
Fig. 4. Involvement of the activation of
EGFR in the phosphorylation of p38 MAPK
and induction of COX-2 protein by methyl-
mercury in human brain microvascular en-
dothelial cells. a) The eﬀect of methylmer-
cury on the phosphorylation of EGFR. The
cells were treated with methylmercury (1–3,
and 5 μM) for 20 min. Western blot analysis
(upper panel) and its quantitative analysis
(lower panel). b) The eﬀect of EGFR in-
hibitor PD153035 on methylmercury-in-
duced phosphorylation of p38 MAPK. The
cells were treated with methylmercury (1–3,
and 5 μM) for 1 h after pretreatment with
PD153035 (2, 5, 10, and 20 μM) for 3 h.
Western blot analysis (upper panel) and its
quantitative analysis (lower panel). c) The
eﬀect of methylmercury on the activity of
PTP1B. The cells were treated with methyl-
mercury (3 and 5 μM) for 20 min. Values are
means ± S.E. of three samples.
Signiﬁcantly diﬀerent from the corre-
sponding control, *p < 0.05; **p < 0.01.
d) The eﬀect of adenylate cyclase inhibitor
SQ22536 on methylmercury-induced ex-
pression of COX-2 protein. The cells were
treated with methylmercury (1–3, and
5 μM) for 24 h after pretreatment with
SQ22536 (10, 20, 50, and 100 μM) for 3 h.
Western blot analysis (upper panel) and its
quantitative analysis (lower panel).
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(Williams, 1979). Accordingly, the induction of PGI2 and PGE2 release
may be a part of the mechanisms underlying the edematous changes in
brains exposed to methylmercury. Note that the PGI2 and PGE2 re-
ceptors are IP and EP, respectively (Ushikubi et al., 1995; Narumiya
et al., 1999), both of which are G protein-coupled. Activation of the IP
receptor increases the intracellular level of cAMP via the activation of
adenylate cyclase. On the other hand, the EP receptor has four subtypes:
EP1, EP2, EP3, and EP4. Among these, EP2 and EP4 increase the in-
tracellular cAMP level by coupling with the Gs protein (Coleman et al.,
1994; Narumiya et al., 1999). Both PGI2 and PGE2 can elevate the
cAMP level via their receptors. Additionally, increased cAMP leads to
activation of protein kinase A (Steinert et al., 2009; El-Haroun et al.,
2008). We reported that methylmercury can activate the paracrine
VEGF system between endothelial cells and pericytes, which can then
enhance vascular permeability via induction of the VEGFR1 expression
in endothelial cells and VEGF-A expression in pericytes (Hirooka et al.,
2013). Since the cAMP level, which can be increased by either PGI2 or
PGE2, increases the expression of VEGF (Höper et al., 1997; Bradbury
et al., 2005), it is suggested that VEGF-A system-induced vascular
permeability is potentiated by cAMP levels in the progression of ede-
matous changes in brains exposed to methylmercury. Additionally,
cAMP mediates the decrease in the anticoagulant heparan sulfate pro-
teoglycan synthesis (Kaji et al., 1996) and ﬁbrinolytic activity (Francis
and Neely, 1989) in vascular endothelial cells, thereby suggesting that
methylmercury can reduce the anti-coagulant and anti-ﬁbrinolytic ac-
tivities that can contribute to the microangiopathy that secondarily
induces damage to nerve cells around the microvessels. Therefore, it is
suggested that increases in PGI2/PGE2 synthesis in vascular endothelial
cells, and that pericytes are signiﬁcantly involved in methylmercury-
induced edematous and inﬂammatory changes in the brain.
Our previous and present studies have worked to clarify the mole-
cular mechanisms underlying the edematous changes that accompany
the inﬂammatory changes leading to secondary nerve cell damage in
brains exposed to methylmercury. Speciﬁcally, it has and continues to
be speculated that the vasogenic edema caused by methylmercury is
initiated by the activation of the VEGF system between the endothelial
cells and pericytes in brain microvessels (Hirooka et al., 2013). When
that occurs, hyaluronan levels increase in the extracellular matrix of
endothelial cells and pericytes (Hirooka et al., 2017). Hyaluronan then
absorbs water seepage from blood vessels whose permeability has been
enhanced by the activated VEGF system following methylmercury ex-
posure. PGI2 and PGE2 would also increase vascular permeability fur-
ther, and thus contribute to the inﬂammatory changes in the progres-
sion of edematous changes caused by methylmercury. Thus, our
experimental results presented in this study provide clear insights into
part of the molecular basis in the “edema hypothesis”, and our obtained
data highlights the importance of vascular toxicity in understanding the
methylmercury neurotoxicity.
It should also be noted that the present study revealed, for the ﬁrst
time, that the presence of methylmercury induced the release of PGI2 in
endothelial cells and pericytes, and in both PGI2 and PGE2 in pericytes.
This was traced to the induction of COX-2 expression mediated by the
EGFR–p38 MAPK pathway. Additionally, we found that PTP1B served
as a sensor protein for methylmercury, and that EGFR was activated by
the inhibition of this enzyme in endothelial cells after methylmercury
exposure. Furthermore, our results suggest that the PGI2/
PGE2–adenylate cyclase–cAMP–protein kinase A pathway provides a
positive feedback loop that increases the COX-2 induction caused by
methylmercury. Since other experimental results show that the acti-
vated cAMP pathway appears to be secondarily and extensively in-
volved in methylmercury neurotoxicity, further studies should be un-
dertaken to clarify the functional damage to brain microvascular cells
as part of eﬀorts aimed at understanding the edematous and in-
ﬂammatory changes caused by methylmercury. However, studies on the
mechanisms underlying not only vasogenic edema, but also cytotoxic
edema, will be necessary from the viewpoint of signal toxicology
(Kanno, 2016) because activation of the PTP1B–EGFR–p38
MAPK–COX-2–PGs–adenylate cyclase–cAMP–protein kinase A signaling
Fig. 5. The present data suggest the intracellular
signal transduction that mediates methylmercury-
induced synthesis of PGI2 in human brain micro-
vascular endothelial cells. Methylmercury inhibits
the activity of PTP1 B and increases the phosphor-
ylation of EGFR. The activated EGFR increases the
phosphorylation of p38 MAPK, and the EGFR–p38
MAPK pathway mediates the methylmercury-in-
duced expression of COX-2 that synthesizes PGI2.
PGI2 stimulates the prostanoid receptor(s) such as
EP2, EP4, and IP that can activate the cAMP
pathway. The cAMP pathway may serve as a positive
feedback loop that enhances PGI2 synthesis via COX-
2 induction.
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cascade may be one of the most important methylmercury signal toxi-
cities.
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